麝香保心丸联合瑞舒伐他汀治疗冠心病的效果

Effect of Shexiang Baoxin Pills combined with rosuvastatin in the treatment coronary heart disease

目的探讨麝香保心丸联合瑞舒伐他汀对冠心病患者血液流变学及外周血微小核糖核酸-126(microRNA-126)、微小核糖核酸-137(microRNA-137)表达水平的影响。方法选取心内科收治的80例冠心病患者作为研究对象,通过随机数字表法分为试验组和对照组,各40例。对照组给予瑞舒伐他汀钙片进行治疗,试验组在对照组治疗的基础上加用麝香保心丸进行治疗,2组均治疗12周。比较2组治疗12周后的临床疗效;对比2组治疗前和治疗12周后的中医证候评分、血脂、血液流变学指标和外周血microRNA-126、microRNA-137表达水平;统计2组治疗期间的不良反应发生率。结果试验组治疗12周后的总有效率高于对照组(92.50%vs.72.50%,P<0.05)。治疗12周后,2组心悸、乏力、胸闷、胸痛评分、总分、血清三酰甘油(TG)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)水平、全血黏度、血浆黏度、纤维蛋白和外周血microRNA-137表达水平较治疗前降低,且试验组低于对照组(P<0.05);2组外周血microRNA-126表达水平较治疗前升高,且试验组高于对照组(P<0.05)。试验组治疗期间的不良反应发生率为10.00%,与对照组(15.00%)比较差异无统计学意义(P>0.05)。结论麝香保心丸联合瑞舒伐他汀治疗冠心病,可明显改善患者的血脂及血液流变学指标水平,并能上调外周血mi-croRNA-126表达,下调外周血microRNA-137表达,调节患者的血管内皮功能,进而有助于改善中医证候,提高疗效,且安全性好。

Objective To investigate the effects of Shexiang Baoxin Pills combined with rosuvastatin on hemorrheology and the expression levels of peripheral blood micro ribonucleic acid-126(microRNA-126),micro ribonucleic acid-137(microRNA-137)in patients with coronary heart disease.Methods A total of 80 patients with coronary heart disease admitted to department of cardiology were selected and divided into the treatment and the control group according to the random number table method,with 40 cases in each group.The control group were given Rosuvastatin Calcium Tablets,and the treatment group were treated with Shexiang Baoxin Pills on the basis of control group.The both groups were treated for 12 weeks.The clinical efficacy in the 2 groups after 12 weeks of treatment was compared;the traditional Chinese medicine(TCM)syndrome scores,blood lipids,blood rheology indexes and the expression levels of peripheral blood microRNA-126 and microRNA-137 in the 2 groups before and after 12 weeks of treatment were compared;the adverse reaction rate during treatment between the 2 groups was counted.Results The total effective rate in the treatment group after 12 weeks of treatment was higher than in the control group(92.50%vs.72.50%,P<0.05).After 12 weeks of treatment,the palpitations,fatigue,chest tightness,chest pain scores,total scores,the serum triacylglycerol(TG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)the whole blood viscosity,plasma viscosity,fibrin and peripheral blood microRNA-137 expression levels were lower than before treatment,and the treatment group was lower than the control group(P<0.05);the expression level of microRNA-126 in peripheral blood was higher than before treatment,the test group was higher than the control group(P<0.05).The adverse reaction rate during treatment in the treatment group was 10.00%,which was not significantly different from the control group(15.00%)(P>0.05).Conclusion Shexiang Baoxin Pills combined with rosuvastatin in the treatment of coronary heart disease could significantly improve the level of blood lipids and blood rheology indicators of patients,and could up-regulate the expression levels of peripheral blood mi-croRNA-126,down-regulate the expression levels of peripheral blood microRNA-137,and regulate the vascular endothelial function in patients.The combination helps to improving the traditional Chinese medicine syndromes and curative effect with high safety.